KADCYLA (ado-trastuzumab emtansine)

OFFICE ADMINISTERED

Indications for Prior Authorization:

HER2 positive, metastatic breast cancer

All of the following must be met as a condition for coverage:

Must have previous treatment with Herceptin® and taxane (separately or in combination)

This Medication is Not Approvable for the following condition(s):

Any condition not listed above as an approved indication.

Dosing:

Recommended dose: 3.6mg/kg IV every 3 weeks (21 day cycle) until disease progression or unacceptable toxicity

Duration of Therapy:

Initial authorization: one year


 

Last review date: December 3, 2013

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone